With a one-of-a-kind platform that can run and analyze millions of experiments at a time, Recursion could change the drug-discovery process. The stock market, though, isn't that impressed, and the ...

Chris Gibson, Recursion Pharmaceuticals CEO, joins 'Closing Bell Overtime' to talk its partnership with Nvidia, its investors day, drug discovery and more. Got a confidential news tip? We want to hear ...